Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis

Figure 1

Clinical outcome of etanercept treatment in rheumatoid arthritis patients. In this cohort study, patients with rheumatoid arthritis (n = 50) and inadequate response to conventional disease-modifying antirheumatic drugs were included. All patients were subjected to etanercept (50 mg once per week) therapy and evaluated according to European League against Rheumatism improvement criteria after 6 months of therapy. (A) Disease Activity Score in 28 joints (DAS28) scores compared between responders (R) and nonresponders (NR) at baseline visit (V1) and at the end of study (V6). (B) Furthermore, C-reactive protein (CRP) levels were measured and compared at V1 and V6.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us